AGP Picks
View all

Tecartus market forecast points to growth through 2035

Nov. 12, 2026
Tecartus market forecast points to growth through 2035
By AI, Created 17:15 UTC, Nov 12, 2026, AGP -

The Business Research Company says the Tecartus market is poised for continued expansion through 2035, driven by rising hematologic cancer cases, broader use of personalized medicine and more investment in CAR-T infrastructure. North America held the largest share in 2025, while the report highlights growth opportunities across Asia-Pacific, Europe, South America, the Middle East and Africa.

Why it matters: - Tecartus is a targeted CAR-T therapy for certain blood cancers, including relapsed or refractory mantle cell lymphoma and B-cell acute lymphoblastic leukemia. - The market outlook matters because demand for personalized cancer treatment is rising while treatment options for hard-to-treat blood cancers remain limited. - The report says the market is set to expand as cell therapy advances and healthcare systems build more capacity for complex oncology care.

What happened: - The Business Research Company released a Tecartus market report covering market size, trends and a global forecast for 2026-2035. - The report says the Tecartus market is progressing because of innovation in cell therapy and stronger demand for personalized cancer treatments. - The report includes a free sample and a full report.

The details: - The historic growth drivers include breakthroughs in cellular immunotherapy, more refractory blood cancer cases, CAR-T approvals, growth in specialized oncology centers and better cell processing logistics. - The forecast period is expected to benefit from more investment in next-generation cell therapies, wider adoption of personalized oncology, decentralized cell manufacturing, greater focus on treatment durability and a larger clinical pipeline for CAR-T indications. - Key trends highlighted in the report include rising CAR-T use, demand for personalized cancer treatments, advances in cell processing technologies, targeted hematologic oncology therapies and deeper use of gene engineering methods. - Tecartus works by engineering a patient’s own T-cells to identify and destroy cancer cells. - The report frames rising hematologic cancer incidence as a primary growth driver for the Tecartus market. - The American Cancer Society estimated about 6,550 new U.S. acute lymphoblastic leukemia cases in 2024, up slightly from 6,540 in 2023. - Higher healthcare spending is also supporting market growth by helping fund centers that can deliver complex CAR-T therapies. - Healthcare Asia Magazine reported in July 2025 that Japan’s public health spending is expected to rise at an average annual rate of 5.0%, from about $416 billion in 2024 to about $531 billion by 2029. - Growing awareness of personalized medicine is supporting demand for autologous CAR-T treatments. - The Personalized Medicine Coalition said the FDA approved 16 new personalized treatments in 2023 for rare diseases, including seven cancer drugs, up from six approvals in 2022. - North America held the largest share of the global Tecartus market in 2025. - The report also covers Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The report points to a market shaped less by broad oncology spending and more by the buildout of specialized infrastructure, manufacturing and clinical pipelines needed for CAR-T therapies. - The emphasis on decentralized manufacturing and durability suggests the market is moving toward broader access and longer-lasting outcomes, not just more approvals. - North America's lead likely reflects stronger research capacity and established healthcare systems, while other regions may be earlier in adoption.

What's next: - The report says future growth will depend on continued investment in next-generation cell therapies and expansion of the CAR-T pipeline. - The Business Research Company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards and market hotspots infographics. - More regional variation is likely as healthcare infrastructure, research capacity and spending levels continue to differ across markets.

The bottom line: - Tecartus sits in a fast-growing but specialized part of oncology, with demand tied to rising blood cancer incidence, personalized medicine adoption and the ability of health systems to deliver advanced cell therapy.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Africa News Guide

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Africa News Guide

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.